Search

Antihemophilic factor, human recombinant

Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

Glutethimide

Its use has been largely superseded by other drugs.

Seladelpar

[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

Tipapkinogene sovacivec

Ularitide

Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. Urodilatin is produced in the kidney and e...

PDPSC18

PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.

Vitex agnus-castus fruit extract

The main mechanism of action of vitex agnus-castus fruit extract has not been fully elucidated, however it is suggested to modulate the stress-induced prolactin secretion via dopaminergic actions, and

Corifollitropin alfa

Corifollitropin alfa is produced by a method known as ‘recombinant DNA technology’. … This means that it is made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa [L2270].

Abetimus

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Cannabidivarin

Compared to its homolog, [DB09061], CBDV is shortened by two methyl (CH2) groups on its side chain. … In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951].